These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8081280)

  • 1. Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML).
    Palatnik-de-Sousa CB; Paraguai-de-Souza E; Gomes EM; Borojevic R
    Braz J Med Biol Res; 1994 Feb; 27(2):547-51. PubMed ID: 8081280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FML (Fucose Mannose Ligand) of Leishmania donovani. a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar.
    Palatnik de Sousa CB; Gomes EM; de Souza EP; dos Santos WR; de Macedo SR; de Medeiros LV; Luz K
    Rev Soc Bras Med Trop; 1996; 29(2):153-63. PubMed ID: 8713607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani.
    Santos WR; Bernardo RR; Peçanha LM; Palatnik M; Parente JP; Palatnik de Sousa CB
    Vaccine; 1997 Jun; 15(9):1024-9. PubMed ID: 9261952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.
    Santos WR; Aguiar IA; Paraguai de Souza E; de Lima VM; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2003 Dec; 21(32):4668-76. PubMed ID: 14585674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani.
    Paraguai de Souza E; Bernardo RR; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2001 Apr; 19(23-24):3104-15. PubMed ID: 11312005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis.
    Palatnik-de-Sousa CB; Gomes EM; Paraguai-de-Souza E; Palatnik M; Luz K; Borojevic R
    Trans R Soc Trop Med Hyg; 1995; 89(4):390-3. PubMed ID: 7570874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani.
    Santos WR; Paraguai de Souza E; Palatnik M; Palatnik de Sousa CB
    Vaccine; 1999 Jun; 17(20-21):2554-61. PubMed ID: 10418902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania infantum FML pulsed-dendritic cells induce a protective immune response in murine visceral leishmaniasis.
    Foroughi-Parvar F; Hatam GR; Sarkari B; Kamali-Sarvestani E
    Immunotherapy; 2015; 7(1):3-12. PubMed ID: 25572475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML).
    Palatnik-de-Sousa CB; Dutra HS; Borojevic R
    Acta Trop; 1993 Mar; 53(1):59-72. PubMed ID: 8096110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
    Saraiva EM; de Figueiredo Barbosa A; Santos FN; Borja-Cabrera GP; Nico D; Souza LO; de Oliveira Mendes-Aguiar C; de Souza EP; Fampa P; Parra LE; Menz I; Dias JG; de Oliveira SM; Palatnik-de-Sousa CB
    Vaccine; 2006 Mar; 24(13):2423-31. PubMed ID: 16386824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.
    Borja-Cabrera GP; Cruz Mendes A; Paraguai de Souza E; Hashimoto Okada LY; de A Trivellato FA; Kawasaki JK; Costa AC; Reis AB; Genaro O; Batista LM; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2004 Jun; 22(17-18):2234-43. PubMed ID: 15149782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine Profile of Leishmania Infantum Fucose-Mannose Ligand in Vaccinated Dogs in the Northwest of Iran.
    Mohammadi-Ghalehbin B; Hatam G; Sarkari B; Mohebali M; Zarei Z; Bohlooli S
    Iran J Immunol; 2017 Dec; 14(4):293-305. PubMed ID: 29276182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).
    Borja-Cabrera GP; Correia Pontes NN; da Silva VO; Paraguai de Souza E; Santos WR; Gomes EM; Luz KG; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2002 Sep; 20(27-28):3277-84. PubMed ID: 12213397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis.
    Santos WR; de Lima VM; de Souza EP; Bernardo RR; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2002 Nov; 21(1-2):30-43. PubMed ID: 12443660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
    Thakur A; Kaur H; Kaur S
    Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the monoterpene, glycidic and triterpene-moieties' contributions to the adjuvant function of the CP05 saponin of Calliandra pulcherrima Benth during vaccination against experimental visceral leishmaniasis.
    Nico D; Santos FN; Borja-Cabrera GP; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2007 Jan; 25(4):649-58. PubMed ID: 17014936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An experimental vaccine providing heterologous protection for Leishmania species in murine model.
    Bebars MA; el Serougi AO; Makled KM; Mikhael EM; Abou Gamra MM; el Sherbiny M; Mohareb AW; Mohammed EA
    J Egypt Soc Parasitol; 2000 Apr; 30(1):137-56. PubMed ID: 10786026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.
    Bhaumik S; Basu R; Sen S; Naskar K; Roy S
    Vaccine; 2009 Feb; 27(9):1306-16. PubMed ID: 19162111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.